Treatment of metastatic non-small-cell lung cancer

Chest Surgery Clinics of North America

Volumn 11, Issue 1, 2001, Pages 133-164

  Johnson, D H ^a   Sandler, A ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; 6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; DOCETAXEL; EPIPODOPHYLLOTOXIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GCP 79787; GEFITINIB; GEMCITABINE; IRINOTECAN; MATRIX METALLOPROTEINASE INHIBITOR; MITOMYCIN; NAVELBINE; PACLITAXEL; PRINOMASTAT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TANOMASTAT; TAXANE DERIVATIVE; TENIPOSIDE; THALIDOMIDE; TIRAPAZAMINE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GENE THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; PATIENT SELECTION;

EID: 0035099625     PISSN: 10523359     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (202)

1. Does cisplatin-based therapy improve survival in extensive non-small cell lung cancer? Southwest Oncology Group studies
2. Survival determinants in extensive-stage non-small cell lung cancer: The Southwest Oncology Group experience
3. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma
4. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer
5. Paclitaxel: What schedule? What dose?
6. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
7. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
8. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer
9. Randomized phase III trial comparing cisplatin/ etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC)
10. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts
11. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes
12. c-Src, receptor tyrosine kinases, and human cancer
13. Carboplatin in non-small cell lung cancer: Review of the Eastern Cooperative Oncology Group trial and comparison with other carboplatin trials
14. Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group (ECOG) trial
15. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: A study of the Eastern Cooperative Oncology Group
16. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract
17. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer
18. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma
19. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC
20. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
21. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization
22. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis
23. The biology of lung cancer
24. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer
25. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer
26. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer
27. Changing views of the role of matrix metalloproteinases in metastasis
28. Activity profile of SU5416, a small molecule Flk-1/KDR inhibitor, in tumor xenograft models
29. Expression of vascular permeability, factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis
30. Extracellular matrix expression in metastasizing and nonmetastasizing adenocarcinomas of the lung
31. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer
32. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: A randomized phase Ill study of the Italian Lung Cancer Project
33. Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life
34. Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 2. Results of a randomised trial in patients with extensive disease
35. Thalidomide is an inhibitor of angiogenesis
36. Quality of life (QOL) assessment in a randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients (pts) previously treated with platinum-based chemotherapy
37. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: A randomized trial
38. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC
39. Phase II study of CPT-11 (irinotecan) in non-mall cell lung cancer (NSCLC)
40. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB
41. Cyclooxygenase, NSAIDs, and colorectal cancer
42. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: The impact of a high-fat diet
43. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group
44. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
45. The cost of managing lung cancer in Canada
46. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
47. Molecular and biological properties of vascular endothelial growth factor
48. Vascular endothelial growth factor
49. Vascular endothelial growth factor, a specific regulator of angiogenesis
50. Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group study
51. Clinical applications of research on angiogenesis
52. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer
53. 2 vs vinorelbine/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (PBC)
54. Gene therapy for lung cancer
55. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer
56. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
57. Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: A phase III study of the Southwest Oncology Group
58. Cisplatin dose intensity in non-small cell lung cancer: Phase II results of a day 1 and day 8 high-dose regimen
59. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?
60. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer
61. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC)
62. Final results of an EORTC phase III study of paclitaxel versus teniposide in combination with cisplatin in advanced NSCLC
63. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group
64. Prognostic value of angiogenesis in operable non-small cell lung cancer
65. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis
66. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts
67. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
68. Tobacco litigation. Issues for public health and public policy
69. Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF MAB) in patients with metastatic cancer
70. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules
71. The relation between funding by the National Institutes of Health and the burden of disease
72. The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression
73. Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer
74. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer
75. Comparison of the cellular pharmacokinetics and toxicity of 2′, 2′-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine
76. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine)
77. Non-small cell lung cancer cyclooxygenase activity, and proliferation are inhibited by non-steroidal antiinflammatory drugs
78. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas
79. Taxol: Mechanisms of action and resistance
80. Oncoprotein networks
81. Prying open the door to the tobacco industry's secrets about nicotine: The Minnesota Tobacco Trial
82. Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance
83. Chemotherapy of lung cancer
84. Preliminary results of a multicenter phase II trial of weekly cisplatin (CDDP) and irinotecan (CPT-11) in patients with advanced non-small cell lung cancer (NSCLC): A Vanderbilt Cancer Center Affiliate Network study
85. 2 in combination with vindesine and mitomycin C in patients with stage IIIB and IV squamous c-cell bronchogenic carcinoma: A randomized phase III study in 221 patients
86. Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992
87. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial
88. E1594 - A randomized phase III trial in metastatic non-small cell lung cancer - Outcome of PS 2 patients: An Eastern Oncology Cooperative Group trial
89. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer
90. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol
91. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes
92. A randomized phase Ill trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology, Group (SWOG) trial
93. neu expression in human lung adenocarcinomas predicts shortened survival
94. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas
95. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients
96. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium
97. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer protocol 07861
98. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small cell lung carcinoma
99. Farnesyltransferase inhibitors: A new class of cancer chemotherapeutics
100. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor
101. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice
102. 2) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC)
103. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans
104. Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer
105. Randomized phase II evaluation of iproplatin (CHIP) and carboplatin (CBDCA) in lung cancer
106. Carboplatin or iproplatin in advanced non-small cell lung cancer: A Cancer and Leukemia Group B study
107. Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
108. Antisense - Time to shoot the messenger
109. SU6668, a broad spectrum angiogensis inhibitor, exhibits potent anti-tumor activity in xenograft models, including regression of established tumors
110. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis
111. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB
112. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
113. Treatment of advanced non-small cell lung cancer: The Southwest Oncology Group experience
114. Relation of neovascularisation to metastasis of non-small cell lung cancer
115. Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3- to 24-hr infusion of high dose Taxol
116. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice
117. Phase Ib trial of intravenous (i.v.) recombinant humanized monoclonal antibody (MAb) to vascular endothelial growth factor (rhuMAbVEGF) in combination with chemotherapy (ChRx) in patients (pts) with advanced cancer (CA): Pharmacologic and longterm safety data
118. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
119. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter phase III study
120. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
121. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma
122. Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer
123. The effect of thalidomide on experimental tumors and metastases
124. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones
125. Synergistic growth inhibition of gemcitabine/ cisplatin, and gemcitabine/etoposide on a human lung cancer cell line, RERF-LC-OK
126. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung
127. Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice
128. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex
129. Randomized multicenter phase III trial of irinotecan (CPT-11) and cisplatin (CDDP) versus CDDP and vindesine (VDS) in patients with advanced non-small cell lung cancer (NSCLC)
130. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
131. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small cell lung cancer treated with combination chemotherapy
132. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
133. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
134. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas
135. Matrix metalloproteinases
136. In vitro dose-response relationship to cisplatin in human non-small cell lung cancer cell lines
137. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer
138. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: An immunohistochemical study on cryosections
139. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
140. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
141. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial
142. Effects of long-term sulindac therapy on colonic polyposis
143. A new schedule of gemcitabine-cisplatin in advanced non-small cell lung cancer (NSCLC) with two different cisplatin dose levels: A phase II randomized trial
144. Gene replacement strategies for lung cancer
145. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
146. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: Cyclophosphamide, doxorubicin, and etoposide versus mitomycin and vinblastine (EST 2575, generation IV)
147. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer
148. Chemotherapy for metastatic non-small cell lung carcinoma: EST 2575, generation V - A randomized comparison of four cisplatin-containing regimens
149. Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II
150. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression
151. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC)
152. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer
153. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer
154. A peptidomimetic inhibitor of farnesyl: Protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines
155. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
156. Tyrosine kinase inhibitors: From the emergence of targets to their clinical development
157. Receptor tyrosine kinases as targets for inhibition of angiogenesis
158. Randomized study of Taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
159. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: A randomized trial comparing two dosages of cisplatin
160. Pattern of practice survey: Non-small cell lung cancer in the US
161. Squalamine inhibits angiogenesis and solid tumor growth in vivo and perturbs embryonic vasculature
162. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa), an inhibitor of EGF receptor tyrosine kinase
163. Nicotine and addiction. The Brown and Williamson documents
164. Addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational controlled phase III trial
165. Attitudes to chemotherapy: Comparing views of patients with cancer with those of doctors, nurses, and general public
166. The current status of camptothecin analogues as antitumor agents
167. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study
168. Duration of chemotherapy for advanced non-small cell lung cancer (NSCLC): A phase III randomized trial of 3 versus 6 courses of mitomycin, vinblastine, cisplatin (MVP)
169. Antisense oligodeoxynucleotides
170. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic
171. Flk-1 as a target for tumor growth inhibition
172. Cyclooxygenase-2 (COX) expression by immunoblot analysis is increased in frequency and amount in primary cancers of the lung and bladder compared with the matched normal tissue
173. Antitumor activity of gemcitabine in combination with cisplatin against the human NSCLC xenograft Calu-6
174. Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies
175. Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion
176. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: Changes in performance status and tumour-related symptoms
177. Improving quality of life in patients with non-small cell lung cancer - Research experience with gemcitabine
178. Gemcitabine: Symptomatic benefit in advanced non-small cell lung cancer
179. Preclinical profile of PK1166 - A novel and potent EGFR tyrosine kinase inhibitor for clinical development
180. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations
181. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu1
182. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells
183. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
184. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
185. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): Response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C
186. Signal transduction by receptors with tyrosine kinase activity
187. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas
188. Inhibition of angiogenesis in vivo by interleukin 12
189. Survival benefit from Triazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients: Final results from the international phase III CATAPULT I trial
190. Aspirin use and potential mechanisms for colorectal cancer prevention
191. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking
192. Antisense oligonucleotides to the epidermal growth factor receptor
193. Expression of cyclooxygenase-2 in human lung carcinoma
194. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer
195. Randomized phase III trial of cisplatin (CDDP) vs. CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): Report of a Southwest Oncology Group study (SWOG-9308)
196. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
197. Regulation of dCMP deaminase in intact CCRF-CEM cells
198. Clarithromycin is a potent inhibitor of tumor-induced angiogenesis
199. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
200. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines
201. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy